Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Обмен на изследователи2015–2018

PRECeDI · Personalized PREvention of Chronic DIseases

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-01-01 → 2018-12-31
Финансиране от ЕС
792 000 €
Участници
12
Схема
MSCA-RISE

Линиите свързват координатора с партньорите.

Накратко на български

Персонализираната медицина изследва индивидуални методи за предотвратяване на хронични заболявания, като например търсенето на биомаркери за рак и сърдечно-съдови проблеми. Това помага за създаването на по-добри здравни политики и модели за генетично тестване на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Personalized PREvention of Chronic DIseases

Medical practitioners are increasingly adopting a 'personalised medicine' (PM) approach involving individually tailored patient care. The PREvention of Chronic DIseases consortium (PRECeDI) project, funded within the Marie Skłodowska Curie Action (MSCA) Research and Innovation Staff Exchange (RISE) scheme, had fostered collaboration on PM research and training with special emphasis on the prevention of chronic diseases. From 2014 to 2018, the PRECeDI consortium trained 58 staff members on personalized prevention of chronic diseases through training and research. The acquisition of skills from researchers came from dedicated secondments from academic and non-academic institutions aimed at training on several research topics related to personalized prevention of cancer, cardiovascular and neurodegenerative diseases. In details, five research domains have been adressed: 1) identification and validation of biomarkers for primary prevention of cardiovascular diseases, secondary prevention of Alzheimer disease, and tertiary prevention of head and neck cancer; 2) economic evaluation of genomic applications; 3) ethical-legal and policy issues surrounding personalized medicine; 4) sociotechnical analysis of the pros-and cons of informing healthy individuals on their genome; 5) identification of organizational models for the provision of predictive genetic testing. Based on the results of the research carried out by the PRECeDI consortium, in November 2018 a set of recommendations for policy-makers, scientists and industry has been issued, with the main goal to foster the integration of personalized medicine approaches in the field of chronic disease prevention.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

The aim of the Personalized pREvention of Chronic DIseases consortium (PRECeDI) is to provide high-quality, multidisciplinary knowledge through training and research in Personalized Medicine (PM), with specific reference to prevention of chronic diseases. There is a large consensus that PM is a driver of innovation for research and health care, and also for the health care system and industry as a whole. In order to harness the potential of this new concept, the PRECeDI consortium provides a cohesive framework for training staff from academic and non-academic (NA) institutions on research topics related to PM, with specific reference to the prevention of chronic diseases where there is a lack of substantial evidence, though the potential is huge. The acquisition of skills from staff will come from dedicated secondments aimed at training on research topics not available at the home institutions, and attendance to courses, workshops, seminars, conferences. The goal of secondment is to enable staff to make informed decisions for appropriately serve health care systems, new biotech industries and policy makers at the dawn of the post-genomic eraPRECeDI is a multidisciplinary group of institutions working on different facets of PM, from basic research, to economic evaluations, health service organization, and ethical, social, and policy issues. The consortium is embedded in existing cooperation structures, such as the PerMed project and the Erasmus Mundus ERAWEB II program, with additional leading SMEs in Europe and Canada as beneficiaries. The consortium consists of 8 beneficiaries and 3 partners, of which 7 are academic institutions and 4 NA, including 2 SMEs. During 4-years, 23 ESRs and 7 ERs will be seconded to 11 institutions, where researchers will be supported by a team of leading EU scientists in PM-related disciplines. In the long run, PRECeDI will foster the integration of PM in the field of prevention, thus contributing to better health for Europe’s citizen

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз